Who We Are
Lexaria Corp. was founded by determined people who have always worked hard to build value both for shareholders and for customers. We have grown to become a revenue-generating biosciences company focused on proprietary technology for improved delivery of bioactive compounds including cannabinoids, through delicious foods. In 2014 we identified scientifically modulated hemp oil delivery as an area of wonderful potential for the Company and its shareholders. Today, we are actively developing and selling hemp oil-based gourmet food products through our subsidiary ViPova™ and under the Lexaria Energy brand. Our business focus has changed over the years but our dedication to customers and shareholders will never waver.
For those of you who have shared our journey over the years, and for new participants as well: thanks for being part of our story.
Mr. Chris Bunka
Chris was appointed Chairman of the Board, CEO and former President in October, 2006. Chris is a serial entrepreneur and has been involved in several private and public companies, since the late 1980’s. He was well known in Canada for more than a decade as a part time business commentator in print and radio, and as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and finance, having assisted in the raising of well over $50 million.
Mr. John Docherty
John became President of Lexaria in the Spring of 2015. Mr. Docherty was former President and Chief Operating officer of Helix BioPharma Corp. (TSX: HBP), where he led the company’s pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.
Mr. Docherty is a senior operations and management executive with over 20 years experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start-ups. At Helix, Mr. Docherty was also instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its board of directors. Prior to this, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for use with a range of active compounds.
Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto.
Mr. Nicholas Baxter
Nick was appointed as a member of the board of directors of Lexaria Corp. in 2009. Nick received a Bachelor of Science (Honours) from the University of Liverpool in 1975, and has worked on oil & gas projects in many areas of the world. Since the 1980’s he has worked with companies in the public markets both in the U.K. and in Canada, and brings extensive real-world experience as a board member.
Mr. Ted McKechnie
Ted was appointed as a member of the board of directors of Lexaria Corp. in 2015. Ted is a senior entrepreneurial executive with extensive Board and Senior Management Experience in the consumer goods industry with a proven track record for achieving corporate financial and growth objectives. He is the former President and COO of Maple Leaf Foods and has held executive positions with Kraft, Frito Lay, General Foods, PepsiCo, and Philip Morris Companies. He is the Founder, Chairman and CEO of Canada’s Technology For Food.
Lexaria is fortunate to be the recipient of widely varying experience and knowledge from a diverse group of advisors who consult with the company from time to time. Each advisor contributes knowledge and experience on an irregular basis in these roles that are less formal than managers or directors. Still, we benefit from their involvement and are grateful for their presence.
Dr. Edward Ergenzinger
Ed serves as outside patent counsel to Lexaria. He is a U.S. licensed patent attorney who also holds a doctorate in Neuroscience (with concentrations in Pharmacology and Physiology). Ed has over 15 years of experience providing patent services to clients that have ranged from small start-ups to some of the world’s largest pharmaceutical and biotechnology companies. His professional experience includes serving as Director of Intellectual Property and Legal Affairs at the Duke Human Vaccine Institute where he managed intellectual property assets arising from over $50 million dollars per year of extramural grants. He also provided seminal patent prosecution and worldwide portfolio management services for a second generation vaccine that generated $4.5 Billion in revenue in 2014. He is lead author or co-author on over forty scientific and legal publications.